We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01862900
Recruitment Status : Active, not recruiting
First Posted : May 27, 2013
Last Update Posted : August 10, 2017
Sponsor:
Collaborators:
Robert W. Franz Cancer Center
Providence Cancer Center
Providence Cancer Center, Earle A. Chiles Research Institute
MedImmune LLC
Information provided by (Responsible Party):
Providence Health & Services

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : February 2018
  Estimated Study Completion Date : February 2023